ATE271865T1 - Verwendung von cholinesterasehemmern zur behandlung von aufmerksamkeitsmangel-störungen - Google Patents
Verwendung von cholinesterasehemmern zur behandlung von aufmerksamkeitsmangel-störungenInfo
- Publication number
- ATE271865T1 ATE271865T1 AT98938759T AT98938759T ATE271865T1 AT E271865 T1 ATE271865 T1 AT E271865T1 AT 98938759 T AT98938759 T AT 98938759T AT 98938759 T AT98938759 T AT 98938759T AT E271865 T1 ATE271865 T1 AT E271865T1
- Authority
- AT
- Austria
- Prior art keywords
- cholinesterase inhibitors
- deficiency disorder
- treat attention
- attention deficiency
- inhibitors
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4425—Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9716879.3A GB9716879D0 (en) | 1997-08-08 | 1997-08-08 | Treatment of attention deficit disorders |
| PCT/GB1998/002378 WO1999007359A1 (en) | 1997-08-08 | 1998-08-07 | Use of cholinesterase inhibitors for treating attention deficit disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE271865T1 true ATE271865T1 (de) | 2004-08-15 |
Family
ID=10817250
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT98938759T ATE271865T1 (de) | 1997-08-08 | 1998-08-07 | Verwendung von cholinesterasehemmern zur behandlung von aufmerksamkeitsmangel-störungen |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP1001761B1 (de) |
| JP (1) | JP2001513496A (de) |
| AT (1) | ATE271865T1 (de) |
| AU (1) | AU8736798A (de) |
| CA (1) | CA2300405C (de) |
| DE (1) | DE69825286T2 (de) |
| DK (1) | DK1001761T3 (de) |
| ES (1) | ES2224421T3 (de) |
| GB (1) | GB9716879D0 (de) |
| TW (1) | TW577742B (de) |
| WO (1) | WO1999007359A1 (de) |
| ZA (1) | ZA987140B (de) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7081238B2 (en) * | 1995-11-03 | 2006-07-25 | The President And Fellows Of Harvard College | Methods for diagnosing and monitoring treatment ADHD by assessing the dopamine transporter level |
| US7553478B2 (en) | 1999-05-12 | 2009-06-30 | President And Fellows Of Harvard College | Methods for diagnosing and monitoring treatment ADHD by assessing the dopamine transporter level |
| JP2003529602A (ja) * | 2000-03-31 | 2003-10-07 | ザノヒェミア・ファルマツォイティカ・アーゲー | ガランタミンの新規誘導体および類似体 |
| ATE487492T1 (de) * | 2003-02-27 | 2010-11-15 | Eisai R&D Man Co Ltd | Pharmazeutische zusammensetzung zur behandlung von drogenabhängigkeit |
| WO2008055945A1 (en) | 2006-11-09 | 2008-05-15 | Probiodrug Ag | 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases |
| US9126987B2 (en) | 2006-11-30 | 2015-09-08 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
| CN101668525A (zh) | 2007-03-01 | 2010-03-10 | 前体生物药物股份公司 | 谷氨酰胺酰环化酶抑制剂的新用途 |
| EP2865670B1 (de) | 2007-04-18 | 2017-01-11 | Probiodrug AG | Thioharnstoffderivative als Glutaminylcyclaseinhibitoren |
| EP2475428B1 (de) | 2009-09-11 | 2015-07-01 | Probiodrug AG | Heterocyclische derivate als glutaminylcyclase-hemmer |
| JP6082250B2 (ja) | 2010-02-09 | 2017-02-15 | ザ・ジョンズ・ホプキンス・ユニバーシティー | 認知機能を改善するための方法および組成物 |
| US9181233B2 (en) | 2010-03-03 | 2015-11-10 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
| AU2011226074B2 (en) | 2010-03-10 | 2015-01-22 | Vivoryon Therapeutics N.V. | Heterocyclic inhibitors of glutaminyl cyclase (QC, EC 2.3.2.5) |
| WO2011131748A2 (en) | 2010-04-21 | 2011-10-27 | Probiodrug Ag | Novel inhibitors |
| DK2686313T3 (en) | 2011-03-16 | 2016-05-02 | Probiodrug Ag | Benzimidazole derivatives as inhibitors of glutaminyl cyclase |
| WO2014078568A1 (en) | 2012-11-14 | 2014-05-22 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
| EP2968220B1 (de) | 2013-03-15 | 2021-05-05 | Agenebio, Inc. | Verfahren und zusammensetzungen zur verbesserung von kognitiven funktionen |
| WO2014144663A1 (en) | 2013-03-15 | 2014-09-18 | The Johns Hopkins University | Methods and compositions for improving cognitive function |
| CA2986598C (en) | 2015-05-22 | 2023-09-26 | Agenebio, Inc. | Extended release pharmaceutical compositions of levetiracetam |
| DK3461819T3 (da) | 2017-09-29 | 2020-08-10 | Probiodrug Ag | Inhibitorer af glutaminylcyklase |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4550113A (en) * | 1982-08-19 | 1985-10-29 | Nauchno-Issledovatelsky Institut Po Biologicheskikm Ispytaniyam Khimicheskikh Soedineny | 9-Amino-2,3,5,6,7,8-hexahydro-1H-cyclopenta(b)quinoline monohydrate hydrochloride as stimulant of neuro-muscular transmission of smooth muscles |
| IL74497A (en) * | 1985-03-05 | 1990-02-09 | Proterra Ag | Pharmaceutical compositions containing phenyl carbamate derivatives and certain phenyl carbamate derivatives |
| DK623586A (da) * | 1985-12-27 | 1987-06-28 | Eisai Co Ltd | Piperidinderivater eller salte deraf og farmaceutiske kompositioner indeholdende forbindelserne |
| US4999430A (en) * | 1989-07-31 | 1991-03-12 | Warner-Lambert Company | Derivatives of 1,2,3,4-tetrahydro-9-acrisinamine |
| US5336675A (en) * | 1991-05-14 | 1994-08-09 | Ernir Snorrason | Method of treating mania in humans |
| TW248556B (de) * | 1993-01-18 | 1995-06-01 | Takeda Pharm Industry Co | |
| PT757685E (pt) * | 1994-04-29 | 2004-10-29 | Pfizer | Novas amidas ciclicas como incrementadores de libertacao de neurotransmissores |
| AU731282B2 (en) * | 1996-06-07 | 2001-03-29 | Eisai Co. Ltd. | Polymorphs of donepezil hydrochloride and process for production |
| AU743609B2 (en) * | 1997-03-03 | 2002-01-31 | Eisai Co. Ltd. | Use of cholinesterase inhibitors to treat disorders of attention |
-
1997
- 1997-08-08 GB GBGB9716879.3A patent/GB9716879D0/en active Pending
-
1998
- 1998-08-07 DK DK98938759T patent/DK1001761T3/da active
- 1998-08-07 ZA ZA987140A patent/ZA987140B/xx unknown
- 1998-08-07 WO PCT/GB1998/002378 patent/WO1999007359A1/en active IP Right Grant
- 1998-08-07 AU AU87367/98A patent/AU8736798A/en not_active Abandoned
- 1998-08-07 EP EP98938759A patent/EP1001761B1/de not_active Expired - Lifetime
- 1998-08-07 JP JP2000506951A patent/JP2001513496A/ja active Pending
- 1998-08-07 AT AT98938759T patent/ATE271865T1/de not_active IP Right Cessation
- 1998-08-07 ES ES98938759T patent/ES2224421T3/es not_active Expired - Lifetime
- 1998-08-07 DE DE69825286T patent/DE69825286T2/de not_active Expired - Fee Related
- 1998-08-07 CA CA002300405A patent/CA2300405C/en not_active Expired - Fee Related
- 1998-08-13 TW TW087113353A patent/TW577742B/zh not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| JP2001513496A (ja) | 2001-09-04 |
| ZA987140B (en) | 1999-03-09 |
| DE69825286T2 (de) | 2005-08-11 |
| WO1999007359A1 (en) | 1999-02-18 |
| EP1001761A1 (de) | 2000-05-24 |
| CA2300405A1 (en) | 1999-02-18 |
| DE69825286D1 (de) | 2004-09-02 |
| AU8736798A (en) | 1999-03-01 |
| CA2300405C (en) | 2008-01-22 |
| EP1001761B1 (de) | 2004-07-28 |
| TW577742B (en) | 2004-03-01 |
| DK1001761T3 (da) | 2004-11-29 |
| GB9716879D0 (en) | 1997-10-15 |
| ES2224421T3 (es) | 2005-03-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE271865T1 (de) | Verwendung von cholinesterasehemmern zur behandlung von aufmerksamkeitsmangel-störungen | |
| DE69815090D1 (de) | Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen | |
| DE60122767D1 (de) | Indoly-lsulphonyl-verbindungen zur behandlung von störungen des zns | |
| DE60015070D1 (de) | Verwendung von antikonvulsiven derivaten zur behandlung der cluster headache | |
| ATE316785T1 (de) | Jak-3 hemmer zur behandlung von allergischen störungen | |
| ATE321548T1 (de) | Verwendung von statin zur behandlung von hauterkrankungen | |
| ATE461697T1 (de) | Phospholipidderivate von valproinsäure und ihre kombinationen | |
| DE60021381D1 (de) | Chinonverbindungen zur behandlung von krankheiten | |
| DE69825440D1 (de) | VERWENDUNG VON TAUROLIDINE ZUR Herstellung eines Arzneimittels zur BEHANDLUNG VON LEUKÄMIEN | |
| ATE210447T1 (de) | Verwendung von cck-b rezeptor antagonisten zur behandlung von schlafstörungen | |
| DE69918972D1 (de) | Verwendung von nmda-antagonisten und/oder natriumkanalantagonisten zur behandlung von entzündlichen erkrankungen | |
| DE69912743D1 (de) | Behandlung von follikulären lymphomen unter verwendung von inhibitoren des lymphotoxin (lt)-aktivierungsweges | |
| ATE217191T1 (de) | Verwendung von phanquinon zur behandlung von alzheimer's krankheit | |
| ATE361071T1 (de) | Verwendung von irbesartan zur vorbeugung oder behandlung pulmonaler hypertonie | |
| ATE402694T1 (de) | Verwendung von 1-phenyl-3-dimethylamino-propan- verbindungen zur therapie der harninkontinenz | |
| ATE420636T1 (de) | Hemmer der protonenabhängigen kationenkanäle und deren verwendung in der behandlung von ischemiebedingten erkrankungen | |
| ATE261724T1 (de) | Antikonvulsive derivate zur behandlung von posttraumatischen stresserkrankungen | |
| DE60009315D1 (de) | Verwendung von cyamemazin zur behandlung von entwöhnungserscheinungen der benzodiazepinbehandlung | |
| DE50010972D1 (de) | UBICHINON Qn ZUR BEHANDLUNG VON MIGRÄNESCHMERZEN | |
| ATE369143T1 (de) | Verwendung von ngali nussöl zur behandlung/linderung der arthritisschmerzen und anderer ähnlichen störungen | |
| ATE357914T1 (de) | Verwendung von 4-aminopyridin zur behandlung von peripheren neuropathien | |
| DE69924385D1 (de) | Verwendung von angiotensin zur behandlung von krebsmetastasierung | |
| DE59904564D1 (de) | Verwendung von acetylcholinesterase-inhibitoren zur behandlung von delirien | |
| ATE297727T1 (de) | Verwendung von anethol-dithiolethion zur vorbeugung und behandlung der sehnentoxizität | |
| DE50105253D1 (de) | Verwendung von n-oleoylethanolamin zur behandlung der schuppenflechte (psoriasis) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1001761 Country of ref document: EP |
|
| REN | Ceased due to non-payment of the annual fee |